Regentis Biomaterials CEO granted 31,250 warrants

REGENTIS BIOMATERIALS LTD. reports that its Chief Executive Officer, Ehud Geller, received a grant of 31,250 warrants to purchase an equal number of ordinary shares at an exercise price of $0.0030 per share.

Rhea-AI Filing Summary

REGENTIS BIOMATERIALS LTD. reports that its Chief Executive Officer, Ehud Geller, received a grant of 31,250 warrants to purchase an equal number of ordinary shares at an exercise price of $0.0030 per share. These currently exercisable warrants were approved by the board on February 23, 2026, received shareholder approval on July 9, 2026, and have a three-year term expiring on February 23, 2029. Following this award, Geller holds 31,250 warrants of this series directly.

Filing Explained

The CEO/director now holds an exercisable warrant for 31,250 ordinary shares at $0.003, without an underlying-share issuance reported here.

The July 13, 2026 Form 4 reports that Regentis’s chief executive officer and director acquired a warrant for 31,250 ordinary shares; it is currently exercisable through February 23, 2029, so the disclosed position is a right to acquire shares rather than an issuance of those shares.

Form 4 code A identifies the transaction as a grant or award, and the filing records the derivative securities as acquired with an exercise price of $0.003, not as an exercise transaction.

The warrant was approved by the board on February 23, 2026 subject to shareholder approval, which the filing says was obtained on July 9, 2026; the warrant has therefore reached the filing’s stated exercisable stage.

The supplied filing does not identify a Rule 10b5-1 plan for this award.

Insider Trade Summary

Grant/Award: 31,250 shares

Grant/Award 1 txn

Insider GELLER EHUD

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Warrants to purchase ordinary shares F1, F2	31,250	$0.00	$0.00

Holdings After Transaction: Warrants to purchase ordinary shares — 31,250 contracts (Direct)

Footnotes (2)

1. F1. This warrant was approved by the Board of Directors of the Issuer on February 23, 2026, subject to shareholder approval, which was obtained on July 9, 2026.
2. F2. The warrants are currently exercisable and have a three year term.

Key Figures

Warrants granted: 31,250 warrants Exercise price: $0.0030 per share Underlying ordinary shares: 31,250 shares +3 more

6 metrics

Warrants granted 31,250 warrants Grant to CEO Ehud Geller reported as of July 9, 2026

Exercise price $0.0030 per share Exercise price for ordinary shares underlying the warrants

Underlying ordinary shares 31,250 shares Ordinary shares issuable upon full exercise of the granted warrants

Warrant expiration date February 23, 2029 Stated expiration date of the three-year warrant term

Board approval date February 23, 2026 Date the board approved the warrant grant, subject to shareholder approval

Shareholder approval date July 9, 2026 Date shareholder approval was obtained for the warrant award

Key Terms

Warrants to purchase ordinary shares, exercise price, shareholder approval, three year term

4 terms

Warrants to purchase ordinary shares financial

"Security title is listed as Warrants to purchase ordinary shares"

exercise price financial

"Conversion or exercise price is disclosed as $0.0030 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

shareholder approval regulatory

"Approved by the Board on February 23, 2026, subject to shareholder approval"

Shareholder approval is a formal vote by a company’s owners—its shareholders—to accept or reject major corporate actions such as mergers, sale of significant assets, board member elections, or changes to the company’s governing rules. It matters to investors because it gives them direct influence over decisions that affect the company’s value and risk profile; think of it like neighbors voting on a large renovation that will change property values, where approval lets the project proceed and rejection stops it.

three year term financial

"The warrants are currently exercisable and have a three year term"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did RGNT CEO Ehud Geller receive in this Form 4 filing?

Ehud Geller, CEO of REGENTIS BIOMATERIALS LTD., received a grant of 31,250 warrants to purchase an equal number of ordinary shares at an exercise price of $0.0030 per share, giving him the right to acquire additional equity.

What is the exercise price of the warrants granted to RGNT’s CEO?

The warrants granted to CEO Ehud Geller carry an exercise price of $0.0030 per share. Each warrant allows the purchase of one ordinary share of REGENTIS BIOMATERIALS LTD. at this price while the warrants remain outstanding.

When do the warrants reported by RGNT for CEO Ehud Geller expire?

The warrants granted to CEO Ehud Geller expire on February 23, 2029. They have a stated three-year term and are currently exercisable, allowing him to purchase ordinary shares any time before that expiration date.

Were the warrants granted to RGNT’s CEO subject to shareholder approval?

Yes. The warrant grant was approved by the board on February 23, 2026, subject to shareholder approval, which was obtained on July 9, 2026. Only after shareholder approval did the award become fully effective.

How many ordinary shares underlie the warrants reported by RGNT?

The reported award consists of 31,250 warrants, each for one ordinary share, so it is exercisable for 31,250 ordinary shares of REGENTIS BIOMATERIALS LTD., assuming full exercise of all the granted warrants.

Are the warrants held by RGNT’s CEO currently exercisable and what is their term?

The filing states the warrants are currently exercisable and have a three year term. Based on the dates provided, this term runs to February 23, 2029, giving the CEO a multi-year window to exercise.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/13/2026 - 05:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GELLER EHUD

(Last) (First) (Middle)

C/O REGENTIS BIOMATERIALS LTD.

60 MEDINAT HAYHEHUDIM

(Street)

HERZLIYA NEW JERSEY 4676652

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
REGENTIS BIOMATERIALS LTD. [ RGNT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrants to purchase ordinary shares(1)(2)	$0.003	07/09/2026		A		31,250		02/23/2026	02/23/2029	Ordinary Shares	31,250	$0	31,250	D

Explanation of Responses:

1. This warrant was approved by the Board of Directors of the Issuer on February 23, 2026, subject to shareholder approval, which was obtained on July 9, 2026.

2. The warrants are currently exercisable and have a three year term.

	/s/ Ehud Geller	07/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)